Tumor idiotype antigen presentation via dendritic cells (null)

Tumor idiotype antigen presentation via dendritic cells describes an immunotherapeutic approach exploiting the unique idiotype antigens found on tumor cell-derived immunoglobulins, particularly those from malignant B cells (e.g., myeloma). These idiotypes, generated by somatic mutation within immunoglobulin variable regions, are highly specific to each tumor clone. Dendritic cells, as professional antigen-presenting cells, can be loaded or "pulsed" with these idiotypes and subsequently present processed antigen peptides to T cells—activating CD4^+^ via MHC class II and CD8^+^ via cross-presentation on MHC class I. This process stimulates both cellular and humoral immune responses and is the basis for idiotype-targeted cancer vaccine strategies. The unique nature of each idiotype offers highly tumor-specific targeting, but efficacy is dependent on overcoming immunosuppression in the tumor microenvironment and avoiding induction of regulatory T cells that could hamper therapeutic benefit.

Other names

Tumor idiotype antigen presentationIdiotype antigen cross-presentation via dendritic cellsIdiotype-pulsed dendritic cellsTumor-specific idiotype DC vaccination

Presentation of tumor idiotype antigens by dendritic cells via MHC class I or II, stimulating CD8^+^ or CD4^+^ T cell responses leading to tumor cell killing